Featured Research

from universities, journals, and other organizations

"Crossover" Drug Effective For Restless Legs Syndrome

Date:
November 26, 2002
Source:
American Academy Of Neurology
Summary:
An anticonvulsant drug typically used to control seizures and neuropathic pain may reduce symptoms among those who suffer from restless legs syndrome (RLS), a movement disorder that affects up to 10 percent of the population.

ST. PAUL, MN – An anticonvulsant drug typically used to control seizures and neuropathic pain may reduce symptoms among those who suffer from restless legs syndrome (RLS), a movement disorder that affects up to 10 percent of the population. A study published in the November 26 issue of Neurology, journal of the American Academy of Neurology, concludes, "Gabapentin may be a potent agent for treatment of even severe RLS, without the disadvantages of long-term complications of previously favored treatments," according to study author Diego Garcia-Borreguero, MD, of the Fundacion Jimenez Díaz in Madrid, Spain.

Related Articles


RLS is characterized by: an urge to move the legs, generally accompanied by unpleasant sensations; an increase of symptoms during rest and a partial, temporary relief of symptoms through activity; and worsening of symptoms in the evening or at night. Symptoms tend to progress with age. RLS is usually treated with dopaminergic drugs, such as those used with Parkinson's disease patients. However, the side effects and likelihood of long-term complications have driven the search for RLS treatment options.

Researchers performed a double-blind study of the effectiveness of gabapentin with 24 patients with RLS, eight men and 16 women. None of the patients had been treated previously with either gabapentin or dopaminergic medications, and any other medications were discontinued at least two weeks before the study began. Patients were randomized and assigned to receive either gabapentin or placebo in the first of two six-week intervals, with a one-week "washout period" between alternating treatments. Physical and neurological examinations were performed at baseline, at the first visit (neurological examination only), and at the end of each treatment period. Patients also completed hourly symptom severity ratings.

Using sleep studies as well as an RLS severity rating scale, a sleep questionnaire, and patients' own perception of clinical symptom change, researchers found treatment with gabapentin improved (reduced) RLS symptoms in the study group. Sleep studies also showed a marked reduction in leg movements, as well as an overall improvement of total sleep time and sleep quality during treatment with gabapentin. "Our study shows dramatic therapeutic effects of gabapentin in RLS under controlled conditions," concludes Garcia Borreguero. "Additional long-term studies are warranted to confirm our outcomes and examine gabapentin tolerance during chronic treatment."

###

The American Academy of Neurology, an association of more than 18,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research.

For more information about the American Academy of Neurology, visit its website at http://www.aan.com.


Story Source:

The above story is based on materials provided by American Academy Of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy Of Neurology. ""Crossover" Drug Effective For Restless Legs Syndrome." ScienceDaily. ScienceDaily, 26 November 2002. <www.sciencedaily.com/releases/2002/11/021126073328.htm>.
American Academy Of Neurology. (2002, November 26). "Crossover" Drug Effective For Restless Legs Syndrome. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2002/11/021126073328.htm
American Academy Of Neurology. ""Crossover" Drug Effective For Restless Legs Syndrome." ScienceDaily. www.sciencedaily.com/releases/2002/11/021126073328.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins